Infectious Disease AdvisorZelsuvmi Now Available for Treatment of Molluscum Contagiosum

Zelsuvmi (berdazimer topical gel, 10.3%) represents the first FDA-approved topical treatment for molluscum contagiosum in patients ≥1 year old. Phase 3 trial data demonstrated 32.4% complete lesion clearance versus 19.7% with vehicle at 12 weeks, offering evidence-based alternative to watchful waiting.

⚕️ Key Clinical Considerations ⚕️

• Efficacy Data: 32.4% complete clearance rate represents modest but statistically significant improvement over placebo (19.7%) in 891-patient phase 3 trial.
• Patient Selection: Approved for patients ≥1 year with molluscum contagiosum; consider for families seeking active treatment over observation.
• Application Protocol: Two-component system requiring daily mixing and application for up to 12 weeks using provided dosing guide.
• Safety Profile: Local application site reactions most common (pain, erythema, pruritus); generally manageable in pediatric population.
• Treatment Duration: Up to 12 weeks of daily application required; counsel families on realistic timeline expectations.

🎯 Clinical Practice Impact 🎯

• Patient Communication: Discuss realistic expectations—one-third clearance rate may justify trial for motivated families versus continued observation.
• Practice Integration: Home-based application reduces clinic visits; consider for patients/families frustrated with watchful waiting approach.
• Risk Management: Monitor for excessive local reactions; educate caregivers on proper mixing technique and application site care.
• Action Items: Evaluate patient assistance program eligibility; establish follow-up protocols for treatment response assessment at 4-6 weeks.

More on Viral Infections